



MARKET RELEASE

25 September 2017

Neurotech International Limited

TRADING HALT

The securities of Neurotech International Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday, 27 September 2017, or when the announcement is released to the market.

Security Code: NTI

Ben Secrett
Senior Adviser, Listings Compliance (Perth)

Neurotech

Anjuli Sinniah

Adviser, Listings Compliance (Perth)
ASX Compliance Pty Ltd
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

Via Email: tradinghaltperth@asx.com.au
anjuli.sinniah@asx.com.au

TRADING HALT

Pursuant to Listing Rule 17.1, Neurotech International Limited (ASX: NTI) (“the Company”) requests a trading halt for its securities for pre-open on Monday 25 September 2017. The trading halt is requested pending the announcement by the Company of a progress update on the independent US clinical trial of Mente Autism.

The Company is not aware of any reason why a trading halt should not be granted.

The Company’s securities are to remain in trading halt until the earlier of the commencement of normal trading on Wednesday 27 September 2017 and when the progress update announcement is released to the market.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform,

Neurotech International Ltd

ABN 73 610 205 402
Level 14, 191 St Georges Terrace
Perth, Western Australia 6060
www.neurotechinternational.com

Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420